Key facts: 2027 FDA bid, Phase 3 trials; analysts cut targets
Celldex Therapeutics plans FDA approval for barzolvolimab in 2027 and is conducting Phase 3 trials. Barclays cut its price target to $50, while HC Wainwright reduced theirs to $58, both maintaining positive ratings. The stock closed at $27.96 on Nov. 19.
How this was made

The 30-second read
Why it matters
Analyst target reductions reflect weaker near‑term expectations, while the FDA timeline adds long‑term uncertainty, likely pressuring the stock.
Market read
The combined analyst downgrades and distant FDA filing create short‑term downside risk for CLDX, with limited broader market impact.
What to watch
Potential partnership or licensing deals for barzolvolimab could mitigate downside if announced.
Background
Celldex (CLDX) announced plans for a 2027 FDA submission for barzolvolimab and ongoing Phase 3 trials, while Barclays and HC Wainwright cut price targets.
Ticker impact
Barzolvolimab FDA bid for 2027 and analyst target cuts to $50/$58 provide fresh corporate and regulatory news for Celldex.
likely pressure as the market prices in lower price targets and the long‑term FDA timeline adds uncertainty
Target reductions from $53 to $50 and $64 to $58 signal weaker expectations; the 2027 FDA filing does not offset short‑term sentiment.
Market effects
Biotech sector may see modest caution on late‑stage trial timelines.
U.S. biotech investors likely to reassess near‑term valuations.
Limited; primarily affects U.S. listed biotech exposure.
Counterpoint
Long‑term investors might view the 2027 FDA filing as a catalyst for future upside despite short‑term target cuts.
Key entities
- CompanyCelldex
Biotech firm developing barzolvolimab.
- Financial InstitutionBarclays
Maintains Overweight rating, cuts target to $50.
- Financial InstitutionHC Wainwright
Retains Buy rating, lowers target to $58.